Actionable news
All posts from Actionable news
Actionable news in IPXL: Impax Laboratories, Inc.,

Changing Landscape for Generic-Drug Makers Creates Opportunities

The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of the majority of the former Actavis generic assets from Allergan.

Allgergan is a holding in Jim Cramer's Action Alerts PLUS Charitable Trust Portfolio. See how Cramer rates the stock here. Want to be alerted before Cramer buys or sells AGN? Learn more now.

Other major deals in the generic sector, which include several stemming from the Teva Pharmaceutical-Actavis deal are:

  • Dr. Reddy's Laboratories purchase of the eight-product portfolio of abbreviated new drug applications from Teva Pharmaceutical (this month)
  • Endo Pharmaceuticals Holdings'acquisition of Par Pharmaceutical (September)
  • Impax Laboratories' purchase of a 15-product portfolio from Teva Pharmaceutical (this month)
  • Mayne Pharma'spurchase of other generic assets from Teva Pharmaceutical (this month)
  • Mylan's purchase of Meda of Sweden (pending) and Abbott Laboratories' generics (February 2015)
  • Nichi-Iko of Japan's acquisition of Sagent Pharmaceuticals...